Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals in the Indo-Pacific DOI Creative Commons
Gizem Mayis Bilgin, Syarifah Liza Munira,

Kamalini Lokuge

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 27, 2023

Abstract Background Decision-makers in middle-income countries need evidence on the cost-effectiveness of COVID-19 booster doses and oral antivirals to appropriately prioritise these healthcare interventions. Methods We used a dynamic transmission model assess Fiji, Indonesia, Papua New Guinea, Timor-Leste. conducted analysis from both societal perspectives using 3% discounting for ongoing costs health benefits. developed an interactive R Shiny which allows user vary key assumptions, such as choice rate, view how assumptions affect results. Findings Booster were cost saving therefore cost-effective all four settings discounting. Providing was perspective if procured at low generic ($25 United States Dollars) or reference price ($250 Dollars); however, their strongly influenced by rates wastage misuse, care patients hospitalised with COVID-19. Interestingly, rapid antigen tests did not appear influential over any study settings. Conclusions Our results support that government funded programs continue be Oral demonstrate potential below $250 USD per schedule. Further research should quantify misuse

Language: Английский

Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs DOI

Darvin Scott Smith,

Maarten J. Postma, David N. Fisman

et al.

Vaccine, Journal Year: 2025, Volume and Issue: 51, P. 126879 - 126879

Published: Feb. 15, 2025

Language: Английский

Citations

1
Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan DOI Creative Commons

Mitsuhiro Nagano,

Kazumasa Kamei,

Hiroyuki Matsuda

et al.

Expert Review of Vaccines, Journal Year: 2024, Volume and Issue: 23(1), P. 349 - 361

Published: Feb. 27, 2024

Background The aim of this study was to evaluate the public health and economic impact COVID-19 booster vaccination with BNT162b2 in Japan during an Omicron-dominant period from early 2022.

Language: Английский

Citations

5
The global mRNA vaccine patent landscape DOI Creative Commons
Mengyao Li,

Jianxiong Ren,

Xingyong Si

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2022, Volume and Issue: 18(6)

Published: July 7, 2022

In light of their quick development and low risk, mRNA vaccines are gradually replacing traditional vaccines. order to characterize the patent landscape vaccines, this study collated vaccine-related applications that have been registered since 1962. Accordingly, 1852 families were discussed in relation temporal distribution, geographic scope, organizational assignees, co-patenting activities. shown demonstrate promise infectious disease, cancer immunotherapy, allergic with a focus on lipid nanoparticles. Notably, these being developed against backdrop fierce industrial competition intensive collaboration rise applications. The findings highlighted cutting-edge inventions, key players, dynamics among institutions. By understanding vaccine patents, researchers those industry may better comprehend latest trends area, which also assist relevant decision-making by academics, government officials, leaders.

Language: Английский

Citations

12
Cost-Effectiveness Analysis of COVID-19 Inactivated Vaccines in Reducing the Economic Burden of Ischaemic Stroke after SARS-CoV-2 Infection DOI Creative Commons
Min Du, Chenyuan Qin, Min Liu

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(5), P. 957 - 957

Published: May 7, 2023

Due to significant economic burden and disability from ischaemic stroke the relationship between SARS-CoV-2 infection, we aimed explore cost-effectiveness of two-dose inactivated COVID-19 vaccination program in reducing after infection. We constructed a decision-analytic Markov model compare strategy no using cohort simulation. calculated incremental ratios (ICERs) evaluate used number cases infection quality-adjusted life-years (QALYs) assess effects. Both one-way deterministic sensitivity analysis probabilistic were performed robustness results. found that reduced by 80.89% (127/157) with USD 1.09 million as cost, saved 3675.69 direct health care costs gained 26.56 QALYs compared among 100,000 patients (ICER < 0 per QALY gained). ICERs remained robust analysis. The proportion older people critical factors affected ICER. This study suggests importance is not only preventing spread infectious diseases, but also considering its long-term value non-communicable diseases such

Language: Английский

Citations

2
Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals: Case studies in the Indo-Pacific DOI Creative Commons
Gizem Mayis Bilgin, Syarifah Liza Munira, Kamalini Lokuge

et al.

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(9), P. e0294091 - e0294091

Published: Sept. 30, 2024

Background Decision-makers in middle-income countries need evidence on the cost-effectiveness of COVID-19 booster doses and oral antivirals to appropriately prioritise these healthcare interventions. Methods We used a dynamic transmission model assess Fiji, Indonesia, Papua New Guinea, Timor-Leste. conducted analysis from both societal perspectives using data collated publicly available sources. developed an interactive R Shiny which allows user vary key assumptions, such as choice discounting rate, view how assumptions affect results. Findings Booster were cost saving therefore cost-effective all four settings 3% discounting. Providing was perspective if procured at low generic price (US$25) or reference (US$250); however, their strongly influenced by rates wastage misuse, ongoing costs care for patients hospitalised with COVID-19. The rapid antigen tests did not appear influential over any study settings. Conclusions Our results support that programs are Oral demonstrate potential be below US$250 per schedule. Further research should quantify misuse

Language: Английский

Citations

0
Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals in the Indo-Pacific DOI Creative Commons
Gizem Mayis Bilgin, Syarifah Liza Munira,

Kamalini Lokuge

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 27, 2023

Abstract Background Decision-makers in middle-income countries need evidence on the cost-effectiveness of COVID-19 booster doses and oral antivirals to appropriately prioritise these healthcare interventions. Methods We used a dynamic transmission model assess Fiji, Indonesia, Papua New Guinea, Timor-Leste. conducted analysis from both societal perspectives using 3% discounting for ongoing costs health benefits. developed an interactive R Shiny which allows user vary key assumptions, such as choice rate, view how assumptions affect results. Findings Booster were cost saving therefore cost-effective all four settings discounting. Providing was perspective if procured at low generic ($25 United States Dollars) or reference price ($250 Dollars); however, their strongly influenced by rates wastage misuse, care patients hospitalised with COVID-19. Interestingly, rapid antigen tests did not appear influential over any study settings. Conclusions Our results support that government funded programs continue be Oral demonstrate potential below $250 USD per schedule. Further research should quantify misuse

Language: Английский

Citations

0